(redirected from Eylea)



Pharmacologic class: Vascular endothelial growth factor (VEGF) inhibitor

Therapeutic class: Ophthalmic agent

Pregnancy risk category C


VEGF-A and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.


Solution for ophthalmic injection: 40 mg/ml in 3-ml (0.278-ml fill) single-use vials

Indications and dosages

Neovascular (wet) age-related macular degeneration

Adults: 2 mg (0.05 ml) by intravitreal injection into affected eye q 4 weeks for the first 3 months, followed by 2 mg (0.05 ml) once q 8 weeks


• Hypersensitivity to drug or its components

• Ocular or periocular infection

• Active intraocular inflammation


Use cautiously in:

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Be aware that drug should be administered by ophthalmic intravitreal injection only under controlled aseptic conditions by a qualified health care professional.

• Provide adequate anesthesia and a topical broad-spectrum anti-infective before the injection, as prescribed.

• Inspect drug for particulate matter and discoloration before administering.

• Use a filter needle to draw up the prescribed dose; remove the filter needle from syringe, and attach a 30G, ½-inch injection needle for the intravitreal injection. Discard unused drug after injection.

• Be aware that each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, use a new vial and change all equipment.

• Immediately following the intravitreal injection, assess patient for increased intraocular pressure (IOC).

Adverse reactions

CNS: nonfatal stroke

CV: nonfatal MI, vascular death

EENT: conjunctival hyperemia, conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, increased IOC, endophthalmitis, corneal erosion, corneal edema, retinal detachment, retinal tear, retinal pigment epithelium tear, injection-site pain, injection-site hemorrhage, foreign body sensation in eye, increased lacrimation, blurred vision, eyelid edema

Other: hypersensitivity



Patient monitoring

• Continue to monitor patient for increased IOP, endophthalmitis, retinal detachment, and arterial thromboembolic events and be prepared to treat appropriately.

Patient teaching

Instruct patient to contact ophthalmologist immediately if treated eye becomes red, light sensitive, or painful, or if vision change occurs.

Instruct patient to immediately report signs and symptoms of stroke (such as weakness on one side of body or slurred speech), chest pain, or other new signs and symptoms.

• Caution patient to avoid driving and other hazardous activities until visual function has recovered sufficiently.

• As appropriate, review all other significant and life-threatening adverse reactions mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
On Tuesday, the company announced FDA approval for its prefilled Eylea syringe.
ENPNewswire-August 14, 2019--Regeneron Pharmaceuticals - FDA Approves EYLEA Injection Prefilled Syringe
M2 EQUITYBITES-August 14, 2019-Regeneron Pharmaceuticals Inc wins US FDA approval for the EYLEA Injection prefilled syringe for macular degeneration and macular edema
Global Banking News-August 14, 2019-Regeneron Pharmaceuticals Inc wins US FDA approval for the EYLEA Injection prefilled syringe for macular degeneration and macular edema
M2 PHARMA-August 14, 2019-Regeneron Pharmaceuticals Inc wins US FDA approval for the EYLEA Injection prefilled syringe for macular degeneration and macular edema
FDA approved EYLEA for diabetic retinopathy and Dupixent for chronic rhinosinusitis with nasal polyposis
* Fourth quarter 2018 EYLEA net sales outside the United States, which are recorded by the Company's collaborator Bayer, increased 14% to $724 million
Bayer and Novartis, who both market drugs for the treatment of wet AMD (Eylea and Lucentis, respectively), challenged the lawfulness of the policy adopted by the CCGs.
Avastin is as effective as Lucentis, a drug made by pharma firm Novartis, and Eylea, produced by Bayer, but is 30 times cheaper.
Lucentis (ranibizumab) and aflibercept (Eylea) are licensed to treat the condition, which is a leading cause of blindness among older patients.
Xarelto, an oral anticoagulant, and Eylea, an eye medicine used for the treatment of wet age-related macular degeneration continued to contribute significant growth to Bayer, mainly because of their expanded use and reach across more markets.